Literature DB >> 3033328

Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

B Wahren, L Morfeldt-Månsson, G Biberfeld, L Moberg, A Sönnerborg, P Ljungman, A Werner, R Kurth, R Gallo, D Bolognesi.   

Abstract

The human immunodeficiency virus (HIV)-specific lymphocyte proliferation response was determined for 40 persons at different stages of HIV infection. The specific response to purified HIV virion antigens from strain HTLV-IIIB was poor, occurred in only 9 of the 40 subjects, was not improved with the addition of interleukin-2, and was more frequent in symptom-free individuals (46%) than in patients with lymphadenopathy syndrome (10%). Reactivity to subcomponent p24 was better than that to whole HIV; reactivity was present in five of six infected persons and increased with the addition of exogenous interleukin-2. Reactivities to subcomponents (g)p41 and gp120 were also measured. This is the first evidence of a specific cell-mediated immune response to HIV antigen in HIV-infected persons. Monkeys immunized with purified HIV or with purified p24 displayed cellular immunoreactivity both to whole HIV and to subcomponents. In contrast to the poor reactivity to HIV antigen, the lymphocytes of the patients had good specific cell proliferation responses to cytomegalovirus and herpes simplex virus challenge and a normal response to the addition of phytohemagglutinin. The results suggest a functional defect in peripheral lymphocytes of some HIV-infected individuals on the basis of their response to whole HIV antigen and a better response to gag protein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033328      PMCID: PMC254211          DOI: 10.1128/JVI.61.6.2017-2023.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Cellular immunity and herpesvirus infections in cardiac-transplant patients.

Authors:  K H Rand; L E Rasmussen; R B Pollard; A Arvin; T C Merigan
Journal:  N Engl J Med       Date:  1977-06-16       Impact factor: 91.245

2.  T-cell ratios in homosexuals.

Authors:  J I Wallace; F S Coral; I R Rimm; H Lane; H Levine; E L Reinherz; S F Schlossman; J Sonnabend
Journal:  Lancet       Date:  1982-04-17       Impact factor: 79.321

3.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

4.  An interchangeable ELISA for cytomegalovirus antigen and antibody.

Authors:  V A Sundqvist; B Wahren
Journal:  J Virol Methods       Date:  1981-04       Impact factor: 2.014

5.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

Authors:  G V Quinnan; N Kirmani; A H Rook; J F Manischewitz; L Jackson; G Moreschi; G W Santos; R Saral; W H Burns
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

6.  Immunological characterization of homosexual males.

Authors:  J M Reuben; E M Hersh; P W Mansell; G Newell; A Rios; R Rossen; A L Goldstein; J E McClure
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

7.  Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity.

Authors:  L K Borysiewicz; S Morris; J D Page; J G Sissons
Journal:  Eur J Immunol       Date:  1983-10       Impact factor: 5.532

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  51 in total

1.  Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers.

Authors:  Sara Ferrando-Martínez; Joseph P Casazza; Manuel Leal; Kawthar Machmach; Ma Ángeles Muñoz-Fernández; Pompeyo Viciana; Richard A Koup; Ezequiel Ruiz-Mateos
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.

Authors:  F Manca; L Walker; A Newell; F Celada; J A Habeshaw; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 3.  Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.

Authors:  Diana Finzi; Susan F Plaeger; Carl W Dieffenbach
Journal:  Clin Vaccine Immunol       Date:  2006-07

Review 4.  Structured treatment interruption in patients infected with HIV: a new approach to therapy.

Authors:  Roy M Gulick
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Authors:  María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

6.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120.

Authors:  C E Hioe; M Tuen; P C Chien; G Jones; S Ratto-Kim; P J Norris; W J Moretto; D F Nixon; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden.

Authors:  R J Trauger; W K Giermakowska; F Ferre; P C Duffy; M R Wallace; D E Lewis; H J Beecham; K G Burnett; F C Jensen; D J Carlo
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

10.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.